Vigil Neuroscience, Inc.
vigilneuro.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Aug 5, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Nov 14, 2025.
10-Q for Q2 FY2025, filed Aug 5, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops an antibody treatment and an oral drug for people with rare and common neurodegenerative diseases, including a rare inherited brain disease and Alzheimer’s disease.
10-K for FY2024, filed Mar 13, 2025We are a clinical-stage biotechnology company dedicated to improving the lives of patients, caregivers, and families affected by rare and…View ↗
Our lead clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 clinical trial and the first-ever interventional…View ↗
In addition to iluzanebart, we are developing VG-3927, our orally bioavailable small molecule TREM2 agonist for the treatment of common…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Aug 5, 2025
−$26.7MView ↗
- ▲ +26% (Loss)
- vs −$21.2M in Q2 FY2024
Who Did They Compete With?
Competes with Novartis, Janssen Pharmaceutica, Elixiron Immunotherapeutics, Biogen, Eli Lilly, and Roche
10-K for FY2024, filed Mar 13, 2025We are aware of third parties which are pursuing therapeutics that target the same molecular targets as our product candidates. Third…View ↗
Loading...
